bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Apple

AbbVie

AGNC Investment

Antero Midstream Partners

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Bank of Montreal

Bank of Nova Scotia

BRT Apartments

Blackstone Group

Blackstone Secured Lending Fund

Colgate-Palmolive

Canadian Imperial Bank of Commerce

Cisco Systems

Investment activity in October focused on Business Development Companies, with $1,300 added to the market. Adjusted dividend income in October of $789, up 25% Y/Y and up 11% sequentially. Main picks included Blackstone Secured Lending, Goldman Sachs BDC, and Midcap Financial Investment Corporation.

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

On Thursday, Bluebird Bio Inc. BLUE reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents.

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

bluebird bio Inc (NASDAQ:BLUE) shares shed more than 11% on Friday after the Massachusetts-based biotech company developing gene therapies for severe genetic diseases was downgraded by Bank of America analysts. The analysts downgraded the company to ‘Neutral' and lowered their price target to $0.50 from $3 on their belief its key product launch, Lyfgenia for sick cell disease (SCD), will ramp slower and achieve lower peak revenue.

bluebird bio downgraded by Bank of America, shares tumble

bluebird bio, Inc. (NASDAQ:BLUE ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director, Investor Relations Andrew Obenshain - Chief Executive Officer Tom Klima - Chief Commercial & Operating Officer James Sterling - Chief Financial Officer Conference Call Participants Jack Allen - Baird Gena Wang - Barclays Jason Gerberry - Bank of America CJ Yeh - Leerink Partners Eric Schmidt - Cantor Fitzgerald Sami Corwin - William Blair Operator Good morning, ladies and gentlemen. Thank you for standing by.

bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript

Bluebird Bio (BLUE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.66 per share a year ago.

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. “Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial launches continued to accelerate,” said Andrew Obenshain, chief executive officer. “This momentum, coupled with steps.

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

The heavy selling pressure might have exhausted for Bluebird (BLUE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it partially adjourned its annual meeting of stockholders (“Annual Meeting”) on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the “proxy statement”). The C.

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio presenting data from gene therapy programs in Sickle Cell Disease and Beta-Thalassemia at the 66th ASH Annual Meeting and Exposition.

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Bluebird Bio (BLUE, Financial) experienced a significant drop in its stock price, declining by 5.67%. The shares are currently trading at $0.491, with a trading volume of 3.72 million shares, a turnover rate of 1.92%, and showing a price amplitude of 4.76%.

Bluebird Bio (BLUE) Stock Dips Amid Market Volatility

Amgen

Biogen

Bristol-Myers

CRISPR Therapeutics

Editas Medicine

Exact Sciences

Intellia Therapeutics

Pfizer

Recursion Pharmaceuticals

Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and contrarian buying opportunities. AI is revolutionizing drug discovery by significantly speeding up the process and increasing the probability of successful outcomes, making it a game-changer for the biotech sector.

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement awards of 242,500 restricted stock units (RSUs). This includes the previously disclosed 100,000 RSUs granted to the Company's CFO, James Sterling, with a grant date of September 30, 2024 and 142,500 RSUs granted to 19 other employees, with a grant date of October 1, 2024 (collectively, the “Inducement Grants”).

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bluebird Bio (BLUE, Financial) stock experienced a notable surge of 5.04% to $0.494 per share. The trading volume reached 6.47552 million shares, resulting in a turnover rate of 3.34% and a volatility of 8.69%.

Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) with the Securities and Exchange Commission (“SEC”). With the completion of this filing, the Company is now current in its SEC periodic reporting obligations. About bluebird bio, Inc. bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. Founded in 2.

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Gene therapy maker bluebird bio said on Tuesday it would cut 25% of its workforce as part of a restructuring program for cost reduction.

Bluebird bio to cut 25% of workforce as part of restructuring

SOMERVILLE, Mass.--(BUSINESS WIRE)--Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company's cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reductio.

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

thredUP

There's a trade that's generally accepted anytime someone makes an investment.

2 Penny Stocks To Buy With Just $250

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022, and for each of the first three quarters of 2022 and 2023. Today, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), including the restated information, and Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 Form 10-Q”) with th.

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Apple Hospitality REIT

Bayerische Motoren Werke AG

Investment activity in July focused on Business Development Companies, with $2,000 added to the market. Adjusted dividend income in July of $709, up 19% Y/Y and down 4% sequentially. Main picks included Blackstone Secured Lending, Ares Capital and Owl Rock Capital.

My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference, Wednesday, September 4, at 12:45 p.m. ET at the Encore Boston Harbor, Everett, MA Morgan Stanley 22nd Annual Global Healthcare Conference, Thursday, September 5, at 5:35 p.m. ET at the New York Marriott Marquis, New York, NY To access the live webcast of.

bluebird bio Announces September Investor Events

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received notices (the “notices”) on August 20, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the “Q1 2024 Form 10-Q”) and June 30, 2024 (the “Q2 2024 Form 10-Q”), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies.

bluebird bio Announces Receipt of Expected Notices from Nasdaq

bluebird bio, Inc. (NASDAQ:BLUE ) Q2 2024 Results Conference Call August 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of Investor Relations Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer James Sterling - CFO Conference Call Participants Jack Allen - Baird Eric Joseph - JPMorgan Gena Wang - Barclays Jeff Hung - Morgan Stanley Luca Issi - RBC Capital Markets Sami Corwin - William Blair Operator Thank you for standing by. My name is Ken and I will be your conference operator today.

bluebird bio, Inc. (BLUE) Q2 2024 Earnings Call Transcript

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported second quarter results and business highlights for the quarter ended June 30, 2024, including recent commercial and operational progress. “We are seeing clear evidence that our commercial launch is accelerating, with over 20 cell collections completed in sickle cell disease and beta-thalassemia to date in 2024, and more than 40 additional patients already scheduled to initiate.

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14, at 8:00 a.m. ET. To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and ask to be joined into the bluebird call or provide the Conference ID 2776050. To access the live webcast, please visit the “Events & Presentations” page within the Investors & Media secti.

bluebird bio Announces Second Quarter 2024 Results Call Date

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 38,200 shares of common stock to its controller and vice president of accounting, Joe Ewer, with a grant date of August 1, 2024. The stock options approved under the Inducement Plan have an exercise price per share equal to $1.08, the fair market value of the Company's common.

bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

News for bluebird bio Stock (BLUE)